NCT06235801View on ClinicalTrials.gov

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2029

Conditions

Myeloid Leukemia

Interventions

DRUG

Gilteritinib

Given by PO

DRUG

Momelotinib

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER